Trial Profile

Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HOMSC 300 (Primary)
Indications Multiple system atrophy
Focus Adverse reactions; First in man
Sponsors CYTORA

Most Recent Events

19 May 2025 According to the CYTORA media release, interim results from this study was presented at the International MSA CONGRESS, BOSTON 2025.
19 May 2025 Results presented in the CYTORA Media Release.
29 Jan 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com